Abstract
Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
CTLA-4 Antigen / immunology*
-
Humans
-
Immunotherapy
-
Ipilimumab
-
Melanoma / immunology
-
Melanoma / therapy
-
Neoplasms / immunology*
-
Neoplasms / therapy*
-
Programmed Cell Death 1 Receptor / immunology*
-
T-Lymphocytes / immunology
-
Translational Research, Biomedical
Substances
-
Antibodies, Monoclonal
-
CTLA-4 Antigen
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor